SPDR Solactive United Kingdom ETF
ZGBR
New York Stock Exchange Arca- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- MA United States of America
- IPO Date
- Jun 11, 2014
- CIK
- 0001168164
- Similar Companies
- Business
- SPDR Solactive United Kingdom ETF (ZGBR) is an exchange-traded fund that seeks to track the performance, before fees and expenses, of the Solactive GBS United Kingdom Large & Mid Cap USD Index NTR (formerly switched from an MSCI index). The fund provides investors with targeted exposure to a free float-adjusted, market capitalization-weighted portfolio of large- and mid-cap companies listed on U.K. exchanges, excluding those on the Alternative Investment Market (AIM); key holdings have historically included major firms such as AstraZeneca plc (AZN), HSBC Holdings plc (HSBA), GlaxoSmithKline plc (GSK), and Diageo plc (DGE). It offers a net expense ratio of 0.14%, with assets under management around $14.6 million and a dividend yield of approximately 3.9%, serving institutional and retail investors focused on U.K. equity market segments. The ETF, issued by State Street Global Advisors (SSGA), a division of State Street Corporation headquartered in Boston, Massachusetts, was launched prior to 2018 as part of the SPDR family of exchange-traded products. SSGA manages the fund's portfolio with a replication strategy, listing shares on the NYSE Arca exchange under the ticker ZGBR. In recent developments, the ETF underwent an index benchmark switch to the Solactive GBS United Kingdom Large & Mid Cap USD Index alongside peer SPDR single-country funds, coinciding with a fee reduction from 30 basis points to 14 basis points. Holdings data was last prominently updated as of March 22, 2021, reflecting ongoing tracking of the broad U.K. market investable universe covering approximately the largest 99% of free-float market capitalization. No major partnerships, acquisitions, new product launches, or operational changes have been announced in the last 1-2 years, with the fund maintaining its strategic focus amid low trading volumes averaging under 5,000 shares daily.